Vol. 21 No. 2 (2022)
Clinical Cases

Metastatic prostate cancer with negative MRI-targeted prostate biopsies: case report

PDF
  • Victor S. Diniz,
  • Celso M. C. Lara,
  • Ronaldo Damião
DOI: https://doi.org/10.12957/bjhbs.2022.71660

Published 2023-01-03

Keywords

  • Prostate Neoplasms,
  • Image-Guided Biopsy,
  • Positron Emission Tomography combined with Computed Tomography,
  • Carcinoma of unknown primary

How to Cite

1.
S. Diniz V, M. C. Lara C, Damião R. Metastatic prostate cancer with negative MRI-targeted prostate biopsies: case report. BJHBS [Internet]. 2023 Jan. 3 [cited 2024 Nov. 7];21(2):156-60. Available from: https://bjhbs.hupe.uerj.br/bjhbs/article/view/18

Copyright (c) 2022 Brazilian Journal of Health and Biomedical Sciences

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.

Crossref
Scopus
Google Scholar
Europe PMC

Abstract

This article presents the case of an asymptomatic patient with ascending PSA and suspected prostate cancer, who underwent two MRI-targeted prostate biopsies, both of which were negative for this neoplasm. PSMA PET/CT revealed secondary bone implant, while the biopsy of the metastatic lesion showed prostate adenocarcinoma. Docetaxel-based chemotherapy associated with androgen deprivation was performed. Despite the high accuracy of MRI-targeted prostate biopsy, diagnosis can occasionally be difficult, and PSMA PET/CT can help to detect distant lesions and aid the diagnosis.

PDF

Metrics

Metrics Loading ...

References

  1. EAU Guidelines. Edn. presented at the EAU Annual Congress Amsterdam 2022. ISBN 978-94-92671-16-5.
  2. Rassy E, Pavlidis N. The currently declining incidence of cancer of unknown primary. Cancer Epidemiol. 2019;61:139. doi: 10.1016/j.canep.2019.06.006.
  3. Katagiri H, Takahashi M, Inagaki J, et al. Determining the site of the primary cancer in patients with skeletal metastasis of unknown origin: a retrospective study. Cancer. 1999;86(3):533. doi: 10.1002/(sici)1097-0142(19990801)86:3<533::aid-cncr24>3.0.co;2-1.
  4. Brazilian Society of Urology. Counseling for the early diagnosis of prostate cancer. 2020 Oct 10. Available from: https://portaldaurologia.org.br/medicos/noticias/aconselhamento-para-o-diagnostico-precoce-do-cancer-de-prostata/
  5. Kasivisvanathan V, Rannikko AS, Borghi M, et al. MRI-Targeted or Standard Biopsy for Prostate-Cancer Diagnosis. N Engl J Med. 2018;378:1767. doi: 10.1056/NEJMoa1801993. Epub 2018 Mar 18.
  6. van der Leest M, Cornel E, Israel B, et al. Head-to-head Comparison of Transrectal Ultrasound-guided Prostate Biopsy Versus Multiparametric Prostate Resonance Imaging with Subsequent Magnetic Resonanceguided Biopsy in Biopsy-naive Men with Elevated Prostate-specific Antigen: A Large Prospective Multicenter Clinical Study. Eur Urol. 2019;75:570. doi: 10.1016/j.eururo.2018.11.023
  7. Bryk, DJ, Llukani E, Taneja SS, et al. The Role of Ipsilateral and Contralateral Transrectal Ultrasound-guided Systematic Prostate Biopsy in Men With Unilateral Magnetic Resonance Imaging Lesion Undergoing Magnetic Resonance Imaging-ultrasound Fusion-targeted Prostate Biopsy. Urology. 2017;102:178. doi: 10.1016/j.urology.2016.11.017
  8. Roehl KA, Antenor JA, Catalona WJ. Serial biopsy results in prostate cancer screening study. J Urol. 2002;167(6):2435-39. doi: 10.1016/S0022-5347(05)64999-3.
  9. Zhang M, Milot L, Khalvati F, et al. Value of Increasing Biopsy Cores per Target with Cognitive MRI-targeted Transrectal US Prostate Biopsy. Radiology. 2019;291:83. doi: 10.1148/radiol.2019180712. Epub 2019 Jan 29.
  10. Lu AJ, Syed JS, Ghabili K, et al. Role of Core Number and Location in Targeted Magnetic Resonance ImagingUltrasound Fusion Prostate Biopsy. Eur Urol. 2019;76:14. doi: 10.1016/j.eururo.2019.04.008. Epub 2019 Apr 30.
  11. Hofman MS, Lawrentschuk N, Francis RJ, et al. Prostate-specific membrane antigen PET-CT in patients with high-risk prostate cancer before curative-intent surgery or radiotherapy (proPSMA): a prospective, randomised, multicentre study. Lancet. 2020;395:1208. doi: 10.1016/S0140-6736(20)30314-7. Epub 2020 Mar 22
  12. Emmet L, Buteau J, Papa N, et al. The additive diagnostic value of prostate-specific membrane antigen positron emission tomography computed tomography to multiparametric magnetic resonance imaging triage in the diagnosis of prostate cancer (PRIMARY): a prospective multicentre study. Eur Urol. 2021;80:682:689. doi: 10.1016/j.eururo.2021.08.002
  13. Meissner VH, Rauscher I, Schwamborn K, et al. Radical prostatectomy without prior biopsy following multiparametric magnetic resonance imaging and prostate-specific membrane antigen positron emission tomography. Eur Urol. 2022;82:156–60. doi: 10.1016/j.eururo.2021.08.002
  14. Nakata S, Nakano K, Takahashi H, et al. A case of prostate cancer diagnosed pathologically by bone metastatic site biopsy. Nippon Hinyokika Gakkai Zasshi. 2005;96(4):507–510. doi: 10.5980/jpnjurol1989.96.507.
  15. Fukumoto R, Soda T, Uehara M, et al. A case of prostate cancer diagnosed by lymphadenectomy. Hinyokika Kiyo. 2012;58(10):557–560. PMID: 23235279
  16. Ueda Y, Higuchii Y, Hashimoto T, et al. Prostate cancer diagnosed through the biopsy of the bone metastatic lesion; a case report. Hinyokika Kiyo. 2007 May;53(5):327-30. Japanese. PMID: 17561720.
  17. Iwamura H, Hatakeyama S, Tanaka Y, et al. A case of metastatic cancer with markedly elevated PSA level that was not detected by repeat prostate biopsy. BMC Res Notes. 2014 Jan 29;7:64. doi: 10.1186/1756-0500-7-64.

Most read articles by the same author(s)